



Bulletin from the Annual General Meeting in IRRAS AB (publ) on 24 May 2022

The Annual General Meeting in IRRAS AB (publ) has been held on 24 May 2022 and in particular the following decisions were resolved.

The Annual General Meeting resolved to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2021. Furthermore, it was resolved that no dividend will be distributed and disposable profits as of 31 December 2021 are carried forward.

The Annual General Meeting also resolved to discharge the board members and the CEO from liability for 2021.

The Annual General Meeting approved the nominating committee's proposal that the board shall consist of five board members. The Annual General Meeting resolved that the total board remuneration shall amount to SEK 2,116,000 of which SEK 540,000 shall be paid to the Chairman of the Board of Directors and SEK 265,000 shall be paid to each of the other board members elected by the General Meeting and who are not employees of the group. Board members who are residents in the United States shall be paid an additional amount of SEK 106,000. For work in the Audit Committee, the remuneration to the Chairman of the Committee amounts to SEK 130,000 and SEK 65,000 to the other member of the Committee. For work in the Remuneration Committee, the remuneration to the Chairman of the Committee amounts to SEK 100,000 and SEK 50,000 to the other member of the Committee. No extra compensation will be paid for participating in other committees. The Annual General Meeting also resolved that the remuneration to the auditor, as previous, shall be paid in accordance with approved invoices.

The Annual General Meeting resolved that the board until the end of the next Annual General Meeting will consist of the members Kleanthis G. Xanthopoulos, Marios Fotiadis, Anita Tollstadius, Eva Nilsagård and Catherine Gilmore-Lawless. Marios Fotiadis was elected chairman of the board. KPMG AB was re-elected as the company's auditor, with Stefan Lundberg as auditor in charge, until the end of the Annual General Meeting of 2023.

The Annual General Meeting approved the board's report on remunerations.

Complete proposals regarding the Annual General Meeting's decisions are available on IRRAS AB's website, www.iras.com.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAS*flow* and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.iras.com.

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

USA

Will Martin
President and CEO
ir@irras.com

Europe

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on May 24, 2022, at 12:15 (CET).